New study results shed light on questions about the effect of combining drugs to treat osteoporosis and what happens after a switch from one drug to another.
(CCR 2015) A number of new osteoporosis treatments are on the near horizon, drawing on a new understanding of bone biology, as described by a speaker at the Clinical Congress of Rheumatology.
A new study suggests the importance of evaluating the vitamin D3 status and screening for comorbid conditions in patients with psoriasis or psoriatic arthritis.
Three eminent rheumatologists have posted their comprehensive textbook of rheumatology online, open-access and free. They are calling it Rheumaknowledgy.
A Miami rheumatologist tells why he has donated $1 million to offer his colleagues in community practice the chance to pursue their own clinical theories.
Antinuclear antibody testing and DEXA both appear on a new Canadian list of rheumatology tests to avoid and on a similar 2013 list from the American College of Rheumatology. There are interesting differences in the other 3 choices.
New data boosts confidence in drug therapies for osteoporosis, but more research in older adults is required.
A review article in the Medical Letter highlights appropriate use and limitations of bisphosphonates, denosumab, and other osteoporosis treatment, along with the associated costs.
A quiz in JAMA uses a case with discordant DXA results to discuss the options in assessment of hip fracture risk in osteoporosis, describing their advantages and drawbacks.
Eliglustat has a better safety profile than the existing approved oral drug for type 1 Gaucher disease, and is easier to take than enzyme replacement therapy.